Valganciclovir hydrochloride contraindications: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 4: | Line 4: | ||
==Contraindications== | ==Contraindications== | ||
Valcyte is contraindicated in patients who have had a demonstrated clinically significant [[hypersensitivity]] reaction (e.g., anaphylaxis) to valganciclovir, [[ganciclovir]], or any component of the formulation.<ref>{{Cite web | last = |first =|title =http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021304s008,022257s003lbl.pdf | url =http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021304s008,022257s003lbl.pdf|publisher =|date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 23:40, 2 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Contraindications
Valcyte is contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation.[1]
References
- ↑ "http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021304s008,022257s003lbl.pdf" (PDF). External link in
|title=(help)
Adapted from the FDA Package Insert.